STAT3 and TP53 mutations associate with poor prognosis in
anaplastic large cell lymphoma

J 2021

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP et. al.

Základní údaje

Originální název

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Autoři

LOBELLO, Cosimo (380 Itálie, domácí), Boris TICHÝ (203 Česká republika, domácí), Vojtěch BYSTRÝ (203 Česká republika, domácí), Lenka RADOVÁ (203 Česká republika, domácí), Daniel FILIP (703 Slovensko, domácí), Marek MRÁZ (203 Česká republika, domácí), I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER (826 Velká Británie a Severní Irsko, domácí), Andrea JANÍKOVÁ (203 Česká republika, domácí) a Šárka POSPÍŠILOVÁ (203 Česká republika, garant, domácí)

Vydání

Leukemia, London, Nature Publishing Group, 2021, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 12.883

Kód RIV

RIV/00216224:14740/21:00119058

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1038/s41375-020-01093-1

UT WoS

000593816000001

Klíčová slova anglicky

ALCL

Štítky

14110212, CF BIOIT, CF GEN, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 10. 2024 14:03, Ing. Martina Blahová

Anotace

V originále

Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK−) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13]. In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.

Návaznosti

GA19-15737S, projekt VaV

Název: Alternativní mechanismy deregulace p53 dráhy u chronické lymfocytární leukémie

Investor: Grantová agentura ČR, Alternativní mechanismy deregulace p53 dráhy u chronické lymfocytární leukémie

GJ19-23424Y, projekt VaV

Název: Imunogenika v sekvencování následující generace: Dešifrování patogenetických mechanismů u lymfoproliferativních poruch

Investor: Grantová agentura ČR, Immunogenetics in the Next Generation Sequencing era: Deciphering the pathogenetic mechanisms in lymphoproliferative disorders

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

675712, interní kód MU

Název: ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer (Akronym: ALKATRAS)

Investor: Evropská unie, ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer, MSCA Marie Skłodowska-Curie Actions (Excellent Science)

90132, velká výzkumná infrastruktura

Název: NCMG II

Citovat

LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP, Marek MRÁZ, I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER, Andrea JANÍKOVÁ a Šárka POSPÍŠILOVÁ. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 5, s. 1500-1505. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-020-01093-1.

@article{1781892,
   author = {Lobello, Cosimo and Tichý, Boris and Bystrý, Vojtěch and Radová, Lenka and Filip, Daniel and Mráz, Marek and MontesandMojarro, I.A. and Prokoph, N. and Larose, H. and Liang, H.C. and Sharma, G.G. and Mologni, L. and Belada, D. and Kamaradova, K. and Fend, F. and GambacortiandPasserini, C. and Merkel, O. and Turner, Suzanne Dawn and Janíková, Andrea and Pospíšilová, Šárka},
   article_location = {London},
   article_number = {5},
   doi = {http://dx.doi.org/10.1038/s41375-020-01093-1},
   keywords = {ALCL},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma},
   url = {https://www.nature.com/articles/s41375-020-01093-1},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1781892
AU  - Lobello, Cosimo - Tichý, Boris - Bystrý, Vojtěch - Radová, Lenka - Filip, Daniel - Mráz, Marek - Montes-Mojarro, I.A. - Prokoph, N. - Larose, H. - Liang, H.C. - Sharma, G.G. - Mologni, L. - Belada, D. - Kamaradova, K. - Fend, F. - Gambacorti-Passerini, C. - Merkel, O. - Turner, Suzanne Dawn - Janíková, Andrea - Pospíšilová, Šárka
PY  - 2021
TI  - STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
JF  - Leukemia
VL  - 35
IS  - 5
SP  - 1500-1505
EP  - 1500-1505
PB  - Nature Publishing Group
SN  - 08876924
KW  - ALCL
UR  - https://www.nature.com/articles/s41375-020-01093-1
N2  - Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK−) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13]. In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.
ER  -

LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP, Marek MRÁZ, I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER, Andrea JANÍKOVÁ a Šárka POSPÍŠILOVÁ. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. \textit{Leukemia}. London: Nature Publishing Group, 2021, roč.~35, č.~5, s.~1500-1505. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-020-01093-1.

Podrobný výpis o publikaci